Compare Novartis AG (NVS) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Novartis AG trades at $154.71 (market cap $295.37B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.7. The key difference: Novartis AG pays a 3.07% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none, and Novartis AG is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NVS | QDTY | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $168.62 | $46.71 |
52-Week Low | $119.31 | $36.57 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.
The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.
QDTY trades at $39.61, down 0.48% with neutral technical signals. The stock shows consistent weekly dividend distributions averaging $0.26-0.30 per share throughout 2026. Technical indicators suggest a balanced market with RSI at neutral levels and bearish moving average signals. Support and resistance cluster around $39-40, indicating tight trading range consolidation.
The outlook remains balanced with dividend income providing stability, though limited fundamental data availability warrants caution. Key risks include market volatility and dependency on ETF distribution strategies. The stock's performance hinges on broader market trends and YieldMax's distribution management effectiveness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
